Replies to post #74100 on Biotech Values

[Biowatch]

10% vs 4% dropout rate?!?

"The rate of discontinuations due to adverse events was 10.4% (46/442) for 900-mcg albinterferon alfa-2b, vs. 4.1% (18/441) for peginterferon alfa-2a."

[rkrw]

Every data point including side effects and dropout rates weren't in their favor. Further, assuming telapravir gets approved all its data is with Pegasys. I'm not completely sure approval will be a cinch. Either way look for Albuferon to be a commercial flop.

[DewDiligence]

HGSI submits BLA for Zalbin (f/k/a/ Albuferon):

http://finance.yahoo.com/news/Human-Genome-Sciences-Submits-bw-557017448.html?x=0&.v=1

Albuferon was once considered a big deal but, in the aftermath of the impressive Bensyta data, it has been relegated to afterthought by many HGSI investors.